Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
McCrimmon RJ, Al Sifri S, Emral R, Mohan V, Sauque-Reyna L, Trescolí C, Lalic N, Alvarez A, Demil N, Coudert M, Shaunik A, Bonnemaire M, Rosenstock J; SoliMix Trial investigators. McCrimmon RJ, et al. Among authors: alvarez a. Diabetes Obes Metab. 2021 Jun;23(6):1221-1231. doi: 10.1111/dom.14354. Epub 2021 Apr 29. Diabetes Obes Metab. 2021. PMID: 33606908 Clinical Trial.
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
McCrimmon RJ, Home P, Cheng A, Giorgino F, Fonseca V, Souhami E, Alvarez A, Picard P, Rosenstock J. McCrimmon RJ, et al. Among authors: alvarez a. Diabetes Obes Metab. 2022 Dec;24(12):2391-2399. doi: 10.1111/dom.14825. Epub 2022 Aug 23. Diabetes Obes Metab. 2022. PMID: 36054624 Free PMC article.
Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA, Hwu CM, Jammah AA, Arteaga-Díaz JM, Djaballah K, Pilorget V, Alvarez A, Vera C, Vikulova O. Malik RA, et al. Among authors: alvarez a. Diabetes Obes Metab. 2024 Jul;26(7):2811-2819. doi: 10.1111/dom.15599. Epub 2024 Apr 18. Diabetes Obes Metab. 2024. PMID: 38637981
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
Liu M, Gu W, Chen L, Li Y, Kuang H, Du J, Alvarez A, Lauand F, Souhami E, Zhang J, Xu W, Du Q, Mu Y; SoliD trial investigators. Liu M, et al. Among authors: alvarez a. Diabetes Obes Metab. 2024 Sep;26(9):3791-3800. doi: 10.1111/dom.15724. Epub 2024 Jun 22. Diabetes Obes Metab. 2024. PMID: 38922731 Clinical Trial.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Rosenstock J, et al. Among authors: alvarez a. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. Diabetes Care. 2021. PMID: 34183429 Free PMC article.
Sex Differences in Long COVID.
Shah DP, Thaweethai T, Karlson EW, Bonilla H, Horne BD, Mullington JM, Wisnivesky JP, Hornig M, Shinnick DJ, Klein JD, Erdmann NB, Brosnahan SB, Lee-Iannotti JK, Metz TD, Maughan C, Ofotokun I, Reeder HT, Stiles LE, Shaukat A, Hess R, Ashktorab H, Bartram L, Bassett IV, Becker JH, Brim H, Charney AW, Chopra T, Clifton RG, Deeks SG, Erlandson KM, Fierer DS, Flaherman VJ, Fonseca V, Gander JC, Hodder SL, Jacoby VL, Kotini-Shah P, Krishnan JA, Kumar A, Levy BD, Lieberman D, Lin JJ, Martin JN, McComsey GA, Moukabary T, Okumura MJ, Peluso MJ, Rosen CJ, Saade G, Shah PK, Sherif ZA, Taylor BS, Tuttle KR, Urdaneta AE, Wallick JA, Wiley Z, Zhang D, Horwitz LI, Foulkes AS, Singer NG; RECOVER Consortium. Shah DP, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2455430. doi: 10.1001/jamanetworkopen.2024.55430. JAMA Netw Open. 2025. PMID: 39841477 Free PMC article.
2,304 results